VSIR and malignant colon neoplasm: Targeting VISTA on antigen presenting cells (APCs) within the TME attenuates its suppressive effects on CD8 T cell activation while increasing antigen presentation and pro-inflammatory functions of APCs in colon cancer [21, 22].